{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:18:18Z","timestamp":1761128298312},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.intimp.2005.04.013","type":"journal-article","created":{"date-parts":[[2005,6,6]],"date-time":"2005-06-06T20:57:20Z","timestamp":1118091440000},"page":"1611-1621","source":"Crossref","is-referenced-by-count":20,"title":["Chemically modified tetracyclines induce apoptosis in cultured mast cells"],"prefix":"10.1016","volume":"5","author":[{"given":"Charlotta","family":"Sandler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katariina","family":"Nurmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken A.","family":"Lindstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Sorsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorne M.","family":"Golub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petri T.","family":"Kovanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari K.","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2005.04.013_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1446","article-title":"Mast cells in inflammatory arthritis","volume":"7","author":"Nigrovic","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.intimp.2005.04.013_bib2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/07853890310001339","article-title":"Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases","volume":"35","author":"Eklund","year":"2003","journal-title":"Ann Med"},{"key":"10.1016\/j.intimp.2005.04.013_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/ar70","article-title":"Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion","volume":"2","author":"Woolley","year":"2000","journal-title":"Arthritis Res"},{"key":"10.1016\/j.intimp.2005.04.013_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.1780400314","article-title":"Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression","volume":"40","author":"Gotis-Graham","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2005.04.013_bib5","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.4049\/jimmunol.151.7.3775","article-title":"IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3","volume":"151","author":"Mekori","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2005.04.013_bib6","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1073\/pnas.88.14.6382","article-title":"Induction of mast cell proliferation, maturation and heparin synthesis by the rat c-kit ligand, stem cell factor","volume":"88","author":"Tsai","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2005.04.013_bib7","doi-asserted-by":"crossref","unstructured":"Juurikivi A, Sandler C, Lindstedt KA, Kovanen PT, Juutilainen T, Leskinen M, et al. Inhibition of c-Kit tyrosine kinase with imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia; a potential approach for treatment of arthritis. Ann Rheum Dis. in press.","DOI":"10.1136\/ard.2004.029835"},{"key":"10.1016\/j.intimp.2005.04.013_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/10454411910020030201","article-title":"Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs","volume":"2","author":"Golub","year":"1991","journal-title":"Crit Rev Oral Biol Med"},{"key":"10.1016\/j.intimp.2005.04.013_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1006588708131","article-title":"Chemically modified tetracycines inhibit human melanoma cell invasion and metastasis","volume":"16","author":"Seftor","year":"1998","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.intimp.2005.04.013_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1006732424102","article-title":"Influence on chemically modified tetracycline on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells","volume":"18","author":"Meng","year":"2000","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.intimp.2005.04.013_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.bjp.0704068","article-title":"Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines","volume":"133","author":"Tolomeo","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.intimp.2005.04.013_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.10168","article-title":"Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model","volume":"98","author":"Lokeshwar","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.intimp.2005.04.013_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1567-5769(02)00213-8","article-title":"Chemically modified tetracyclines induce cytotoxic effects against J774 tumour cell line by activating the apoptotic pathway","volume":"3","author":"D'Agostino","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.intimp.2005.04.013_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2004.02.028","article-title":"Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors","volume":"35","author":"Holmes","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.intimp.2005.04.013_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.drup.2004.04.002","article-title":"Chemically modified tetracyclines as inhibitors of matrix metalloproteinases","volume":"7","author":"Acharya","year":"2004","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.intimp.2005.04.013_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00011-005-1358-5","article-title":"Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells; possible involvement of protein kinase C","volume":"54","author":"Sandler","year":"2005","journal-title":"Inflamm Res"},{"key":"10.1016\/j.intimp.2005.04.013_bib17","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.4049\/jimmunol.159.6.2624","article-title":"Functional effects of overexpression of protein kinase C-alpha, -beta, -delta, -epsilon, and -eta in the mast cell line RBL-2H3","volume":"159","author":"Chang","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2005.04.013_bib18","doi-asserted-by":"crossref","first-page":"22109","DOI":"10.1016\/S0021-9258(18)45677-3","article-title":"Protein kinase C plays an inhibitory role in interleukin 3- and interleukin 4-mediated mast cell proliferation","volume":"265","author":"Chaikin","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.intimp.2005.04.013_bib19","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood.V78.9.2354.2354","article-title":"Protein kinase C regulates proliferation of mast cells and the expression of the mRNAs of fos and jun proto-oncogenes during activation by IgE-Ag or calcium ionophore A23187","volume":"78","author":"Baranes","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2005.04.013_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"10.1016\/j.intimp.2005.04.013_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1084\/jem.180.1.67","article-title":"Mouse bone marrow-derived mast cells (mBMMC) obtained in vitro from mice that are mast cell-deficient in vivo express the same panel of granule proteases as mBMMC and serosal mast cells from their normal littermates","volume":"180","author":"Eklund","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2005.04.013_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000236932","article-title":"Characterization of cord\u2013blood-derived human mast cells cultured in the presence of steel factor and interleukin-6","volume":"107","author":"Saito","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.intimp.2005.04.013_bib23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0002-9440(10)63512-2","article-title":"A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening","volume":"163","author":"Islam","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.intimp.2005.04.013_bib24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2001.19.2.584","article-title":"Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer","volume":"19","author":"Rudek","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2005.04.013_bib25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0022-2143(97)90130-X","article-title":"Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells","volume":"130","author":"Fife","year":"1997","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.intimp.2005.04.013_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S8756-3282(00)00297-0","article-title":"Tetracyclines induce apoptosis in osteoclasts","volume":"27","author":"Bettany","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.intimp.2005.04.013_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V88.2.386.bloodjournal882386","article-title":"Molecular thanatopsis: a discourse on the BCL2 family and cell death","volume":"88","author":"Yang","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2005.04.013_bib28","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1182\/blood-2002-12-3921","article-title":"A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival","volume":"102","author":"Cohen-Saidon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2005.04.013_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011083031272","article-title":"Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL","volume":"21","author":"Mekori","year":"2001","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2005.04.013_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1126\/science.1411571","article-title":"Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C","volume":"258","author":"Nishizuka","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.intimp.2005.04.013_bib31","doi-asserted-by":"crossref","first-page":"12190","DOI":"10.1073\/pnas.92.26.12190","article-title":"d-Alpha-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties","volume":"92","author":"Tasinato","year":"1995","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757690500113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757690500113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T12:43:40Z","timestamp":1706273020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757690500113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S156757690500113X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2005.04.013","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}